EQS-Adhoc: Ad-hoc: CompuGroup Medical SE & Co. KGaA intends to reduce the annual dividend for the financial year 2024 to the legal minimum

The general partner and the supervisory board of CompuGroup Medical SE & Co. KGaA (the „Company“) (ISIN: DE000A288904 | WKN: A28890) intend to propose to the annual general meeting that only the legally required minimum shall be paid out as dividend for the financial year 2024. This would result in a distribution of EUR 0.05 per dividend bearing share (previous year: EUR 1.00), assuming an unchanged amount of treasury shares. The proposal is made against the backdrop of the Company’s long-term innovation and growth strategy, including investments in infrastructure and resources for greater proximity to customers as well as AI-based processes and products. It further considers, based on the prepared consolidated financial statements, the development of revenue and profitability in the financial year 2024 in line with the adjusted full-year forecast.

According to the prepared consolidated financial statements, the Company generated revenues of approx. EUR 1.154 billion in the financial year 2024 (previous year: approx. EUR 1.188 billion). The organic revenue decreased by around two per cent year-on-year. Adjusted EBITDA decreased by around 15 per cent to approx. EUR 224.6 million (previous year: approx. EUR 264.8 million). The adjusted earnings per share amounted to approx. EUR 1.27 (previous year: approx. EUR 2.06).

A dividend payment based on the final dividend proposal of the general partner and the supervisory board for the financial year 2024 is subject to the approval by the annual general meeting, which is expected to be held in August 2025, as well as further legal requirements.

CompuGroup Medical SE & Co. KGaA will publish the full annual report for the financial year 2024 as planned on March 6, 2025.

“Adjusted EBITDA” and “adjusted earnings per share” are defined in the annual report for the financial year 2023 on p. 45 et seq.